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Comparison of four independently-derived hydrolytic 
antibodies reveals striking similarities in their active sites. A 
common structural motif appears to be induced when the 
immune system is challenged with antigens containing aryl 
phosphonate and phosphonamidate groups, and key variations 
on this ‘theme’ must account for the observed differences in 
catalytic efficacy and mechanism. The limited structural 
repertoire accessed through standard immunization 
procedures suggests that new approaches may be needed to 
produce antibody catalysts with enzyme-like efficiencies. 
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Introduction 
Many biological processes depend on the selective hydrol- 
ysis of esters and amides. In nature, efficient and often 
highly specific enzymes promote these reactions, affording 
exacting control over such events as blood clotting, fertil- 
ization, and complement activation [l-3]. As a result, much 
effort has been directed towards investigating the basic 
principles underlying enzyme-catalyzed ester and amide 
hydrolysis. Many attempts have been made to mimic these 
systems to test and increase our understanding. One 
promising approach has tapped the enormous diversity of 
the mammalian immune system to obtain antibody mole- 
cules with tailored hydrolytic properties. Here we review 
some recent insights into the catalytic mechanism of a 
number of these antibodies and discuss their implications 
for generating catalysts with enzyme-like efficiency. 
Hydrolytic antibodies 
In 1969, Jencks [4] predicted that antibodies elicited 
against stable analogs of reaction transition states would 
catalyze the corresponding reactions. Since then, almost 
100 antibodies with catalytic properties have been reported 
[5,6]. Of these, well over half accelerate the hydrolysis of 
activated ester substrates. Ester and amide hydrolysis is 
known to involve transient formation of a high energy 
intermediate which subsequently decomposes to the corre- 
sponding acid and alcohol or amine. The high energy inter- 
mediate and its flanking transition states can be mimicked 
effectively using phosphonates or phosphonamidates (Fig. 
1). Such analogs resemble the reaction transition states in a 
number of ways, including tetrahedral geometry, negative 
charge, and increased bond lengths. Consequently, these 
molecules have been used widely both as effective 
Figure 1 
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Generalized hydrolysis of an aryl ester or anilide. The corresponding 
phosphonate (X = 0) or phosphonamidate (X = NH) transition state 
analog mimics the geometric and charge properties of the high energy 
oxyanion intermediate and its flanking transition states. 
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inhibitors of hydrolytic enzymes [7-lo] and as haptens 
(immunizing agents) to generate hydrolytic antibodies [5]. 
Recently, structural information has become available for 
four different hydrolytic antibodies, affording further in- 
sight into the basis of antibody catalysis. The haptens used 
in these studies and the corresponding reactions are shown 
in Figure 2. In each case, the same general strategy was 
employed, namely immunization of a mouse with an 
arylphosphonate or arylphosphonamidate hapten, followed 
by monoclonal antibody production using standard 
hybridoma techniques [ll]. The antibodies produced by 
the hybridoma cell lines were then screened for hapten 
recognition and for catalytic activity. The four studies were 
performed independently in different laboratories, using 
different mice, and different haptens, and the resulting 
antibodies catalyze their target reactions with significantly 
different efficiency. Yet when the structures are compared, 
Figure 2 
striking similarities become apparent. The independent 
experiments did not yield four distinct solutions to the 
problem of phosphonate (phosphonamidate) binding and 
ester (amide) hydrolysis, as we might have expected given 
the enormous diversity of the immune response. Instead, a 
central ‘theme’ has emerged upon which are built unique 
variations that must account for the observed differences in 
catalytic efficiency and mechanism. 
CNJ206: the basic theme 
Antibody CNJ206 was generated with phosphonate la 
and selected for its high affinity binding to the short trans- 
ition-state analog lb [12]. The selection strategy was 
designed to narrow the pool of antibodies to those that 
specifically recognized elements of the hapten that 
program for catalysis. The resulting collection of clones 
yielded several antibodies that hydrolyze the correspond- 
ing activated ester substrate 2b with rate enhancements 
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Phosphonate/phosphonamidate haptens used to generate four different hydrolytic antibodies: CNJ206 [12], 17E8 [181, 48G7 I261, and 43C9 
1281. The corresponding reactions catalyzed by the antibodies are shown in black. 
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kkl,C,, ) of 103-104. One of these antibodies, CNJZOG, 
accelerates the hydrolysis of 2b by a factor of 1600, 
achieves multiple turnovers, and exhibits substrate speci- 
ficity consonant with the structure of the inducing hapten. 
Recently, the structure of CNJ206 complexed with the 
short transition-state analog lb was solved to 3.2 A reso- 
lution [13]. In addition, the structure of the uncom- 
plexed antibody was solved to 3.0 A resolution 1141, 
enabling the assessment of ligand-induced conforma- 
tional changes. Like all antibodies, CNJZOG forms its 
ligand-binding site chiefly from loops at the end of the 
variable domains of the heavy (H) and light (L) chains. 
These loops are known as complementarity-determining 
regions (CDRs). In the absence of ligand, the binding 
site of CNJ206 forms a long, shallow groove instead of 
the deep pocket that is characteristic of antibodies that 
bind small molecules. The shallowness of the groove 
results primarily from the orientation of TyrH97 (Tyr97 
of the heavy chain, Kabat numbering system [ 15]), which 
sits in the active site in such a way as to prevent the 
formation of a deep cavity. 
Upon ligand binding, however, large conformational 
changes take place in the antibody (Fig. 3) [13]. The vari- 
able domains of the heavy and light chains realign, under- 
going a 7” rotation with respect to each other and a 0.9 A 
translation parallel to the axis of rotation. In addition to 
this global rearrangement, a significant conformational 
change is observed in the CDR3 loop of the heavy chain 
(CDRH3; GlyH95 to TyrH102) (Fig. 3). Notably, the 
phenyl ring of TyrH97, which occludes the binding 
pocket in the unliganded antibody, rotates 90” to enlarge 
the cavity and allow the phosphonate ligand to become 
Figure 3 
Stereo pair showing the co nformational 
changes that occur in antibody CNJ206 
upon binding its hapten. The complexed 
antibody is shown in white, with its CDRH3 
loop in blue and hapten 1 b in orange. The 
uncomplexed antibody is colored pale green, 
with its CDRH3 loop bright green, The 
crystal structures were superimposed using 
the backbone atoms of residues 1 to 107 of 
the light chain and residues 1 to 90 of the 
heavy chain (root-mean-square deviation of 
1.06A for 1608 atoms). 
engulfed in the active site, where 95 %  of its surface is 
sequestered from solvent. 
In the complex, the ligand is oriented with its p-nitro- 
phenyl group located at the bottom of a deep, apolar 
pocket where hydrophobic and van der Waals interactions 
predominate. Its phosphonate group is located at the 
mouth of the cavity and forms specific hydrogen bonds 
with the antibody (Fig. 4a; see also Fig. 6a). The side 
chain of HisH35 donates one hydrogen bond to the pro-R 
phosphonate oxygen, while two more hydrogen bonds 
form between the pro-S oxygen and the backbone NH 
groups of AspH96 and TyrH97. These observations 
suggest that CNJ206 functions according to the mecha- 
nism programmed by its hapten. It appears to be a rela- 
tively simple catalyst that facilitates direct hydroxide 
attack on the scissile carbonyl of p-nitrophenyl esters by 
stabilizing the oxyanion intermediate and flanking transi- 
tion states through specific hydrogen bonding interac- 
tions. The observed rate acceleration of 1600 corresponds 
roughly to the contribution of a single oxyanion binding 
residue in the serine protease subtilisin [16,17]. 
17E8: a variation on the theme with increased activity 
Like CNJ’206, antibody 17E8 was generated against an 
arylphosphonate hapten [18]. In this case, however, the 
hapten (phosphonate 5) did not contain a nitro group in 
the aromatic moiety and differed significantly in the 
aliphatic side chain (Fig. 2). Antibody 17E8 catalyzes the 
enantioselective hydrolysis of unactivated phenyl esters of 
N-formyl-L-norleucine (6, X = CH,) and N-formyl-L- 
methionine (6, X = S) with rate enhancements of around 
lo4 over background (Table 1). It is thus a significantly 
more active catalyst than CNJ206. The pH-rate profile for 
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Figure 4 (facing page) 
Crystal structures of three hydrolytic antibodies complexed with their 
cognate haptens. (a) CNJ206 [131, (b) 17E8 [19], (c) 48G7 [241. The 
backbone and surface rendering of the heavy and light chains of each 
antibody are shown in cyan and pink, respectively. Left panel: Connolly 
surface representation of the antibodies, using a solvent sphere of 
radius 1.4 A. Center and right panels: Stereo pair, displaying the side 
chains of active site residues identified in Table 2. Of the residues that 
bind the ligand, only residue H98 in CNJ206 and residue L49 in 17E8 
and 48G7 have been omitted for clarity; these make relatively 
unimportant contacts with the alkyl group of the hapten. 
the antibody is bell-shaped, suggesting that two ionizable 
groups may be involved in catalysis. 
Despite the differences in their haptens, CNJ’206 and 
17E8 exhibit striking similarities in their combining sites 
(Fig. 4,5a). As with CNJ206, 17E8 binds its hapten with 
the aryl leaving group buried deeply at the bottom of an 
apolar binding pocket (Fig. 4b) [19], and uses many of 
the same residues as CNJ206 to form this site. In the 
CNJ206*lb complex, five residues come within 3.5 A of 
the p-nitrophenyl moiety of the ligand: LeuL89, 
HisH35, ValH37, TrpH47, and TrpH103. Significantly, 
all five of these important binding-site residues are iden- 
tical in 17E8 (Table 2). Moreover, among the 10 residues 
in total that contact the arylphosphonate moiety of the 
hapten in CNJZ06, seven are identical in 17E8 and 
another is changed conservatively (GlyH95+Ser). This 
contrasts with a more modest overall sequence identity 
of 48 %  for the heavy chain variable region (V,) and 
59 %  for that of the light chain (V,). The high degree of 
sequence conservation in the active site arises in part 
from the fact that both antibodies enlist several frame- 
work residues to form the base of the binding pocket 
(Table 2). Nevertheless, many CDR residues are also 
conserved, as is the overall mode of hapten binding. As 
expected, greater individuality is seen in those regions 
that contact components of the two haptens that are not 
common to both. The many similarities are remarkable, 
however, and raise some interesting questions. 
The fact that several framework residues are used in the 
active site supports this hypothesis. It has been estimated 
that the primary immunoglobulin repertoire contains - lOa 
different antibodies and that this diversity is further 
expanded by several orders of magnitude through the 
process of somatic hypermutation [20,21]. However, the 
presence of a preformed pocket able to accommodate the 
aryl group in haptens such as these may quickly restrict 
the primary response to a much narrower subset of struc- 
tures. Within this subset or ‘theme’, the variation of a few 
key residues could then lead to the observed differences 
in binding and catalytic properties. 
Clearly, the response of the immune system to the two 
arylphosphonate haptens has a common theme, even 
though the germline sequences that were used to generate 
the two antibodies are different. Does this indicate a 
strong bias in the immune system, predisposing the 
response to a particular solution or family of solutions? 
For catalysis, the important variations should be in res- 
idues that form stabilizing contacts with the phosphonyl 
oxygens of the transition-state analog. Comparing 17E8 
with CNJ’206, it is clear that 17E8 provides more exten- 
sive interactions with the phosphonate group than does 
CNJ206 (Fig. 6). In addition to the hydrogen bond from 
the backbone NH of H96 (which is present in both anti- 
bodies), the side chains of two cationic residues, LysH93 
and ArgL96, provide complementary electrostatic/hydro- 
gen bonding interactions with the pro-S and pro-R phos- 
phony1 oxygens, respectively. It is likely that these 
interactions account for the greater catalytic efficiency 
afforded by 17E8 relative to CNJ206 (Table 1). Cationic 
residues are known to be very effective in stabilizing 
oxyanions. In the case of carboxypeptidase A, mutagene- 
sis of a single arginine residue implicated in oxyanion 
binding resulted in a 20 OOO-fold loss of activity [22,23]. 
In addition, the side chain of ArgL96 appears poised to 
complement the incipient negative charge on the pheno- 
late oxygen. In CNJ206, this residue is replaced by a 
tyrosine, which is less able to accommodate the negative 
charge. Electrostatic stabilization of the leaving group 
may thus explain the ability of 17E8, but not CNJ206, to 
Table 1 
Kinetic parameters for the four hydrolytic antibodies discussed in the text, 
Antibody Substrate PH kc&, 
(M-l min-l) 
kat 
(min-l) 
Reference 
CNJ206 
48G7 
17E8 
43c9 
43c9 
2b 8.0 5000 0.4 1600 12 
10a 8.2 14000 5.5 16000 24 
6, X=CH, 8.7 390 000 100 13000 18 
14, x=0 9.3 28 000 000 1500 27 000 29,32 
14, X=NH 9.0 140 0.08 250 000 28.32 
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Figure 5 
The binding sites of the three st 
characterized hydrolytic antibod 
remarkably similar. (a)-(c) Pair-’ 
of the hydrolytic antibodies corn 
their respective haptens. CNJ2( 
white, with hapten 1 b in orange 
shown in yellow, with hapten 5 i 
4867 is shown in cyan, with ha 
pink [24]. (d) Overlay of all threl 
17E8 and 4867 were superimp 
CNJ206 using all the heavy ator 
conserved active site residues 1 
TyrL91, PheL98, HisH35, ValH: 
and Trp H103 (root-mean-squal 
152 atoms of 1 .Ol A for 17E8/( 
1.05A for 48G7ICNJ206). 
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Table 2 
Sequence comparison of the active site residues of four 
hydrolytic antibodies. 
Residue Locationa CNJ206 48G7 17E8 43c9 
L36 FR2 L-L Y-Y 
L89 CDR3 L -----,L ~ i Q 
L96 CDR3 r b -----R-R 
L98 FR4 F-F -:$-F 
H33 CDRl G Y A N 
H35 CDRl H- i-l------- H-H 
H37 FR2 V- v-----v-v 
H47 FR2 W  -w -W-W 
H93 FR3 A-A K V 
CDR3 
ii 
I, 3 
H95 5% S Y 
Hi03 FR4 -w------ -w W  
L34 CDRl S G------ G’ A 
L46 FR2 R-R r.< - L 
L49 FR2 Y-----Y H Y 
L91 CDR3 Y- ~ H 
H96 CDR3 D ;i .,-.L& 
d’ 
G 
H97 CDR3 Y 
H98 CDR3 iv G----- 
I$$ ~ Y 
s& - G 
Residues are colored to indicate the parts of the haptens to which 
they make the most contacts: arylphosphonate moiety blue, linker pink, 
and alkyl side chain green. TyrH96 makes significant contacts with 
both the arylphosphonate and linker moieties in 4867 and is colored 
accordingly. Contact residues were identified by the program 
CONTACSYM [58], using a distance threshold of 4.33 A. 
aFR, framework region; CDR, complementarity determining region. 
catalyze the hydrolysis of unsubstituted aryl esters. The 
simplest interpretation of these observations is that 17E8 
functions in a manner similar to that predicted for 
CNJZ06, with direct hydroxide attack on the scissile car- 
bony1 promoted by numerous stabilizing interactions 
with the resulting oxyanion. The more extensive interac- 
Figure 6 
tions afforded by 17E8 would then account for its 
increased efficacy. 
An alternative mechanism for 17E8 has been proposed, 
involving rate-limiting formation of a covalent acyl-anti- 
body intermediate [l&19]. Modeling studies based on the 
structure of the antibody-hapten complex led to the 
hypothesis that SerH95 is transiently acylated during 
catalysis [19]. Since it is observed to be hydrogen-bonded 
to TyrH97 and directed out of the binding pocket in the 
crystal structure, the proposed mechanism involves a 
novel pH switch. The tyrosine becomes deprotonated at 
high pH, freeing the serine to rotate into the active site. It 
was suggested that HisH35 could then act as a general 
base and activate the serine for nucleophilic attack on the 
substrate’s scissile carbonyl. 
Although an appealing analogy can be made between this 
Ser-His dyad and the Ser-His-Asp catalytic triad of serine 
proteases [19], the hypothesis must be viewed with some 
skepticism for a number of reasons. First, the mechanism 
is based on hydroxylamine partitioning data, which show 
inconsistencies between the hydroxylamine-dependent 
rates of phenol release and quantitation of the hydrox- 
amic acid product [18]. Second, there is no apparent 
chemical advantage to forming an alkyl ester as an inter- 
mediate in the cleavage of the relatively labile aryl-ester 
substrate 6. It is also unclear why hydrolysis of such an 
intermediate would be faster than its formation. Third, if 
HisH35 is to participate in the proposed mechanism, it 
must break a highly conserved hydrogen bond with the 
indole NH of framework residue TrpH47. This interac- 
tion is preserved in many antibody structures, including 
TyrH97 0 AspH96 
\ ,H 
\ ;o*’ 
HisH35 
R 
ArO“ 
. ..p.C- 
‘O-e- HN 
WN 
0 
LysH93 
TyrH96 
A N’ 
0 
TyrH96 
A 
HisH35 
N’ I 
TyrH33 
ArgL96 
Schematic depiction of the hydrogen bonds and salt bridges formed with the phosphonate moiety of the bound haptens in three hydrolytic 
antibodies. The interactions are inferred from the crystal structures of the complexed antibodies and are expected to be important for 
transition-state stabilization during ester hydrolysis. 
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those of CNJ206 [13] and 48G7 [24] (discussed below). 
Finally, a closely related antibody, 29Gl1, which has a 
glycine at position H9.5 but is otherwise identical to 17E8 
Ln all other active site residues [25], is only four-fold less 
active than 17E8 and exhibits a similar pH-rate profile. 
The suggestion that 17E8 forms a covalent acyl interme- 
diate consequently seems unlikely, unless more evidence 
san be provided in its favor. 
5867: variation in the mode of binding 
The similarity between CNJ206 and 17E8 leads us to ask 
how much variation we can expect to see among other 
antibodies obtained using similar haptens. For example, 
will all such antibodies employ the same conserved 
oocket to bind the aryl leaving group, or can this vary to 
some extent? The recent structure of a third esterolytic 
antibody provides us with further insights. 
4ntibody 48G7 [26] was generated against the p-nitro- 
shenyl phosphonate hapten 9a, nearly identical to the 
hapten used to produce CNJ206. It accelerates the 
hydrolysis of activated ester 10a and carbonate lob 
oy factors of 1.6 x lo4 and 4 x lo4 respectively, falling 
between CNJZ06 and 17E8 with respect to its catalytic 
properties (Table 1). Sequence comparison between 
18G7 [26] and the other two antibodies [l&18] reveals a 
high degree of conservation in the binding-site residues. 
3f the ten amino acids in CNJ206 that contact the 
arylphosphonate moiety of the bound hapten, seven are 
Identical in 48G7. The same is seen for 17E8, where 
eight of the ten contact residues are preserved in 48G7 
[Table 2). Again, the overall sequence identity among 
the three antibodies is more modest, although CNJ206 
and 48G7 appear to share a common light chain (92.5% 
sequence identity for V,). 
Given the degree of sequence conservation among 
active-site residues, we might expect 48G7 to bind its 
ligand in the same way as do CNJ206 and 17E8. Surpris- 
ingly, this is not the case. Although the cavity that 
accommodates the aryl moiety of the hapten in both 
CNJ206 and 17E8 is also found in 48G7, it lies empty 
(Fig. 4c) [24]. The phosphonyl group occupies the same 
location, but the aryl group is turned, lying in an adja- 
cent pocket not present in CNJ206. We cannot, however, 
rule out the possibility that the productive mode of sub- 
strate binding is different, since the crystal structure pro- 
vides only a static picture of a dynamic system. It is 
interesting that the second pocket is also present in 
17E8, where it accommodates the alkyl side chain of 
hapten 5 (Fig. 4b). 48G7 might therefore catalyze the 
hydrolysis of phenyl or p-nitrophenyl esters of L-nor- 
leucine, L-methionine, or L-phenylalanine. The pres- 
ence of a branched side chain in the substrate would 
force the leaving group to bind in the unoccupied cavity 
of 48G7, mimicking the binding mode of 17E8. 
Despite the variation in ligand orientation observed in 
4867, the overall theme is maintained: the apolar binding 
pocket is conserved (though unoccupied), the aryl moiety 
of the hapten is buried, and the phosphonate group is 
held in place through specific electrostatic and hydrogen 
bonding interactions near the mouth of the pocket. In 
fact, when the three antibody structures are overlaid, the 
phosphonate groups of the bound haptens occupy a 
similar location (Fig. 5). Not surprisingly, the largest dif- 
ferences are seen in the heavy-chain CDR3 loop, but 
these differences do not affect the overall motif. With 
respect to catalysis, important variations are evident in 
how the antibodies bind the phosphonate group and 
hence are expected to stabilize the corresponding transi- 
tion-state species (Fig. 6). Like CNJ206 and 17E8, 4867 
uses the backbone NH of residue H96 to bind the pro-S 
oxygen of the hapten. In addition, the imidazole group of 
HisH35 donates a second hydrogen bond to this oxygen. 
The pro-R oxygen is stabilized by a salt bridge with 
ArgL96 (seen in 17E8) and a hydrogen bond with the side 
chain of TyrH33. The latter interaction is unique to 
4867; CNJ206 and 17E8 have a glycine and an alanine in 
this position, respectively. 
As for CNJ206 and 17E8, the most likely mechanism for 
48G7 involves direct hydroxide attack on the scissile car- 
bony1 of the substrate. Mutagenesis studies on 48G7 have 
investigated the importance of HisH35, ArgL96, and 
TyrH33 for catalysis: changing these residues respectively 
to Glu, Gln, and Phe results in a reduction in k,,, of 30-, 
1 l-, and 3.2-fold [24]. The effects for ArgL96 and TyrH33 
are relatively small, and it has been proposed that this 
reflects the ability of one residue to compensate for the 
other when one of the interactions with the oxyanion is 
lost [‘24]. However, high solvent accessibility and/or con- 
formational mobility of these residues could also account 
for the results. 
43C9: covalent catalysis, an unexpected variation 
The simple mechanism employed by CNJ206, 17E8, and 
4867 arises directly from the common strategy used to 
generate the catalysts. The phosphonate hapten programs 
for direct hydroxide attack on the corresponding sub- 
strate, facilitated by specific stabilizing interactions with 
the oxyanionic transition-state species. It is surprising, 
then, that we observe a more sophisticated mechanism 
employed by a fourth hydrolytic antibody, 43C9 [27]. 
Analogous to the other three catalysts, 43C9 was gener- 
ated using phosphonamidate hapten 13, designed to 
mimic the transition-state species formed during the 
hydrolysis ofp-nitroanilides (Fig. 2) [28]. This catalyst is 
one of the most active hydrolytic antibodies reported 
to date and a rare example of an amidase. At pH 9.0, 
43C9 accelerates the hydrolysis ofp-nitroanilide I4 by a 
factor of 2.5 x lo5 (k,,,/k,,,,,) [28]. It also hydrolyzes the 
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corresponding ester substrate, albeit with somewhat 
diminished efficiency relative to the uncatalyzed reaction 
(k&“,cat = 2.7 x 104) [29]. Mutagenesis experiments 
[30,31] and extensive steady-state and pre-steady-state 
kinetic data [27,32] support a two-step mechanism. In the 
first step, nucleophilic attack of the substrate by an 
active-site histidine yields a covalent acyl-antibody inter- 
mediate. Deacylation by hydroxide ion in the second step 
releases the acid product and regenerates the antibody 
catalyst. The intermediate does not accumulate under 
most conditions, but was detected by electrospray mass 
spectrometry at pH 5.9 [33]. 
Although no crystal structure of 43C9 complexed with its 
hapten is available, homology modeling has been applied 
in an effort to understand this catalyst’s unique properties 
[30]. The model of 43C9 was constructed in a step-wise 
fashion using an antibody structural database. First, appro- 
priate framework residues were selected based on 
sequence comparison. Then, the CDRs were modeled 
using structural templates from antibodies with closely 
related sequences. Although the conformation of five of 
the CDRs could be predicted with reasonable confidence, 
CDRH3 could not be modeled successfully since highly 
homologous sequences were unavailable. Nevertheless, 
the V, and V, domains were paired and the hapten 
docked into the active site. In a final step, the H3 loop was 
optimized by manual adjustment and energy minimization 
of the side-chain positions. 
Sequence comparison of 43C9 [34] with each of the other 
hydrolytic antibodies discussed above reveals a reasonably 
high degree of conservation among active-site residues 
(Table 2). In particular, 43C9 most closely resembles 
Figure 7 
Stereo pair showing the crystal structure of 
17E8 [19], superimposed on the homology 
model of 43C9 [30]. 17E8 is shown in 
yellow, with hapten 5 in green. 43C9 is 
shown in pink, with hapten 13 in blue. The 
overlay demonstrates the similarities between 
the two antibodies, as well as the difference 
in the predicted binding mode of hapten 13 
in 43C9 relative to that of hapten 5 in 17E8. 
The structures were superimposed using the 
backbone atoms of residues L89, L91, L98, 
H35, H37, H47, and H103 (root-mean- 
square deviation of 0.56A for 56 atoms). 
17E8. Of the 10 residues that contact the aryl moiety of 
the hapten in 17E8, 7 are identical in 43C9 and another is 
altered conservatively (LeuL89+Gln). As we might 
expect, the homology model of 43C9 has many similarities 
to the crystal structure of i7E8. Where the model deviates 
most is in the conformation of CDRHS and in the orienta- 
tion of the bound hapten (Fig. 7). Notably, this is also 
where the greatest uncertainty in the model lies, due to 
the unavailability of suitable structural templates for the 
CDRH3 loop and to the possibility of substantial ligand- 
induced conformational changes in the binding site (as 
exemplified by CNJ206, Fig. 3). In the model of 43C9, the 
hydrophobic pocket that is used to bind the aryl leaving 
group in 17E8 (and CNJ206) is occupied by the side 
chains of two CDRH3 residues, PheHlOOb and TyrH9.5. 
Hapten 13 was therefore docked in a rather shallow 
depression on the antibody surface to allow the formation 
of a salt bridge between its phosphonate moiety and the 
guanidinium group of ArgL96 [30]. Although a distinctive 
binding mode for this ligand cannot be ruled out, it seems 
equally plausible that the modeled conformation of the 
H3 loop is incorrect and that 43C9 recognizes its hapten in 
much the same way as 17E8, burying the aryl leaving 
group deep within the combining site and forming numer- 
ous stabilizing interactions with the phosphonamidate 
moiety near the mouth of the active site. This hypothesis 
would help to explain the finding that p-nitrophenol 
release limits the rate of ester hydrolysis at high pH. 
The unprogrammed mechanism of 43C9 leads us to ask 
what distinguishes it from the other three hydrolytic anti- 
bodies. Extensive mutagenesis studies on 43C9 have 
revealed the importance of three active-site residues. 
Changing ArgL96 to Gln resulted in a >ZO-fold loss in 
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activity, consistent with its importance in transition-state 
stabilization [30]. This arginine is also present in 17E8 
and 4867, where it presumably has a similar role. Muta- 
genesis of two histidine residues, HisH35 and HisL91, 
also yielded inactive variants of 43C9 [31]. Interestingly, 
substitutions for HisH35 not only affected catalysis but 
also gave proteins with substantially reduced affinities for 
the hapten and products. In contrast, modifications of 
HisL91 had little effect on binding. These results were 
interpreted in favor of a structural role for HisH3.5 and a 
catalytic role for HisL91 as the active-site nucleophile. 
Failure to detect a covalent intermediate by electrospray 
mass spectrometry when a HisL91+Gln mutant was 
incubated with the ester substrate has been cited as 
further evidence for the transient acylation of HisL91 
during catalysis [32]. 
Nucleophilic catalysis may explain why 43C9, but not 
17E8, can cleave an acyl derivative that contains the rela- 
tively poor p-nitroanilide leaving group. Although this is 
not programmed by the hapten, 43C9 adopts a similar 
strategy to that used by serine proteases, dividing a diffi- 
cult reaction into a series of more tractable steps. Since 
17E8 is so similar in its combining site to 43C9, it would 
be interesting to replace TyrL91 in 17E8 with a histidine 
residue to determine whether the properties of the 
mutated antibody approximate those of 43C9. In a 
complementary experiment, introduction of a lysine 
residue in place of ValH93 in 43C9 might provide 
additional transition-state stabilization. 
Evolution of the immune response 
The structural and biochemical information for the 
hydrolytic antibodies discussed above has contributed 
significantly to our understanding of antibody-mediated 
hydrolysis of esters and amides. In particular, we have 
learned that the immune system adopts a common theme 
in constructing an appropriate binding site for these 
related ligands. Within this motif, variations are observed 
that must account for the differences in catalytic effi- 
ciency. Each antibody employs its own set of interactions 
for transition-state stabilization, some of which are shared 
by the other catalysts and some of which are unique (Fig. 
6). In this respect, the antibodies resemble the products 
of convergent evolution. 
The emergence of a principal theme among different 
antibodies that recognize the same ligand has also been 
observed in a number of model studies. When A/J strain 
mice are immunized with a protein conjugate ofp-azo- 
phenylarsonate, most of the antibodies produced share a 
cross-reactive idiotype that results from the combina- 
tion of a single set of gene segments: V, IdCR, 
DFL16 le and JH2 for the heavy chain, and V,lO and JK1 
for the’light chain [35]. The murine immune response to 
Z-phenyl oxazolone (phOx) is also dominated by a 
particular combination of heavy and light chain V 
regions (dubbed V,-0x1 and VK-0x1) [36]. Interest- 
ingly, when a phOx-binding antibody was found with a 
unique V, region (only 48 % homologous to V,-0x1), 
its structure showed that important antigen-binding 
residues had been conserved [37]. This parallels the 
similarities noted among the four hydrolytic antibodies 
discussed here, where sequence conservation is gener- 
ally greatest among ligand-contacting residues. Exten- 
sive sequence analysis of other phOx-binding antibodies 
led to the conclusion that the mouse immune system 
uses a very limited number of principal mechanisms to 
recognize this antigen [37]. A similar conclusion was 
reached by Padlan et al. [38] based on analogous studies 
with mouse anti-phosphorylcholine antibodies. Appar- 
ently, the strong selective pressure imposed by the 
immune system quickly reduces the broad diversity ini- 
tially present in the antibody repertoire to a small 
number of the best solutions. 
Is binding-site diversity increased significantly as the 
immune response is refined through somatic hypermuta- 
tion? To answer this, we must compare mature, high- 
affinity antibodies with their germline precursors. This 
was recently accomplished for 48G7; the parent anti- 
body was cloned, sequenced, and expressed [24]. It was 
found that, during the course of affinity maturation, nine 
amino acid changes had accumulated in its variable 
domain, six in the heavy chain and three in the light 
chain. The germline antibody bound its hapten with a 
dissociation constant (Kd) of 13.5 PM; the mature anti- 
body, 4867, had a K, of 4.5 nM. As expected, the cat- 
alytic efficiency of the antibody improved as its affinity 
for the transition-state analog increased. However, the 
30 OOO-fold increase in affinity from germline to mature 
antibody only gave an ?&fold increase in the apparent 
second-order rate constant, ko,/KM. Thus, only a small 
fraction of the newly acquired binding affinity is used 
for transition-state stabilization. 
How did the process of somatic hypermutation lead to the 
increase in affinity? In the crystal structure of the 
48G709a complex, none of the nine residues that were 
altered during affinity maturation makes direct contact 
with the ligand. Although six of the nine mutations occur 
in the CDRs, the residues surround the binding pocket. 
Similar results have been obtained in other studies of 
somatic mutations 13537,391. In each case, most or all of 
the changes occur in residues that are not in direct 
contact with the hapten. Recently, Winter and coworkers 
[40] carried out an extensive analysis of the entire human 
V, and V, repertoires. They compiled a database of 1181 
rearranged V, and 736 rearranged V, sequences and 
identified the location of somatic mutations in each 
sequence. Mapping this information onto the structure 
of a representative antibody led to the conclusion that 
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sequence diversity is focused at the center of the binding 
site in the primary repertoire, but spreads to regions at 
the periphery of the binding site during somatic hyper- 
mutation. They propose that ‘evolution has favored this 
complementarity as an efficient strategy for searching 
sequence space’. The changes that accumulate as the 
antibodies are refined probably either reorganize the 
active-site residues via conformational changes, optimiz- 
ing their geometries for hapten binding, or limit the flexi- 
bility of the active-site loops, reducing the entropic cost 
incurred by binding the ligand. 
Implications 
In the case of 48G7, all the important residues involved 
in transition-state stabilization were already present in its 
germline precursor. The process of affinity maturation 
served mainly to refine the existing motif, presumably by 
‘tightening’ the structure through improved packing and 
secondary hydrogen-bonding interactions. Does this 
suggest that the immune system is intrinsically limited as 
a source of highly active catalysts? Enzymes like subtil- 
isin, a natural counterpart of hydrolytic antibodies, use 
complex constellations of residues that are precisely 
aligned for catalysis in their active sites [41,42]. Such 
arrays may be unavailable in the primary repertoire of the 
immune system and (given the results discussed here) 
may not be accessible through somatic hypermutation. 
At present, it is not clear how much activity can be 
obtained from the motif shared by the antiphosphonate 
antibodies. We have seen that different residues may be 
used to stabilize the transition state, with differing degrees 
of effectiveness. Moreover, the study of 43C9 shows that 
unprogrammed mechanisms analogous to those used by 
natural enzymes can arise, albeit through serendipity. Yet, 
although 43C9 is quite a sophisticated catalyst, it is still 
primitive compared to highly-evolved enzymes like subtil- 
isin. For example, p-nitroanilide hydrolysis by 43C9 (k,,, = 
1.3 x 10” s-l at pH 9.0, 37 “C [ZS]) is more than 30 000 
times less efficient than the subtilisin-catalyzed cleavage 
of succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (k,,, = 44 s-r at 
pH 8.0, 25 “C [16]). Can we expect to bridge this gap, or 
are we forever limited by the bounds imposed by the 
immune system? 
If we are to achieve the goal of enzyme-like efficiency, it 
may be necessary to explore new approaches for optimiz- 
ing catalytic activity. In the case of ester and amide 
hydrolysis, we have learned that a common theme pre- 
sents itself in response to the haptens employed in these 
studies. The phosphonate moiety is positioned near the 
mouth of the pocket, with the phosphonyl oxygens 
directed laterally and the leaving group deeply buried. In 
contrast to this, several natural proteases, including car- 
boxypeptidase A [43], thermolysin [44], and ol-lytic pro- 
tease [45], bind phosphonate inhibitors with the 
phosphonyl oxygens directed toward the base of the 
pocket and the leaving group and acid moieties posi- 
tioned laterally. To mimic this mode of binding, we may 
have to use novel haptens that provide access to different 
subsets of the primary immunoglobulin repertoire. Alter- 
natively, in vitro selection methods, such as phage display 
technology [46], can free us from the particular predispo- 
sitions of the immune system (although they may intro- 
duce new biases). Semisynthetic antibody libraries 
[47,48], or even libraries composed of receptors com- 
pletely unrelated to the immunoglobulin fold, may also 
be used to obtain novel binding sites [49]. 
New functional groups could conceivably be introduced 
into first-generation antibody catalysts by site-directed 
mutagenesis. This offers a way to circumvent the low 
probability of obtaining complex constellations of cat- 
alytic residues in a single step. Heterologous immuniza- 
tion 1501 and the use of mechanism-based inhibitors as 
templates [51] may also allow the induction of multiple 
properly oriented catalytic residues. The use of organic 
cofactors [52,53] or metal ions [54] presents an alterna- 
tive way to promote energetically demanding chemical 
transformations. In concert with such approaches, it may 
be necessary to alter the strategy of selection. Compar- 
ing h&&,,,,,) with log(KiL1/Ki) for a wide range of 
antibody catalysts indicates that as the affinity of the 
antibody for its hapten increases (Ki gets smaller), a 
lower proportion of the binding energy is used to stabi- 
lize the transition state relative to the ground state of 
the substrate [55]. This emphasizes the need to opti- 
mize existing catalysts by selecting directly for catalytic 
activity [26,56,57] instead of for affinity for an inevitably 
imperfect transition-state analog. An incremental 
approach will probably be required in which modest cat- 
alysts are improved by multiple rounds of mutagenesis 
and selection. 
Attempts to produce more efficient catalytic antibodies 
through alternative strategies such as these will benefit 
greatly from the accumulating biochemical and structural 
data. For the antibodies discussed above, such informa- 
tion has already ratified the basic approach taken to gen- 
erate these catalysts and provides us with the 
mechanistic understanding we need to direct our future 
efforts. Continued probing of these active sites, coupling 
mutagenesis with structure determination, promises to 
provide additional insight, not only into antibody-medi- 
ated hydrolysis, but into the promotion of hydrolytic 
reactions more generally. 
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